-
公开(公告)号：US07947496B2
公开(公告)日：2011-05-24
申请号：US11364013
申请日：2006-02-28
CPC分类号： C07K16/2884 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/73 , G01N33/5082 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
-
公开(公告)号：US20100015045A1
公开(公告)日：2010-01-21
申请号：US12504473
申请日：2009-07-16
IPC分类号： A61K51/00 , A61K39/395 , A61P35/04 , G01N33/574 , C12N5/00 , C12N5/02 , C07K16/00
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3046 , C07K2317/56
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。
-
53.发明申请Cytotoxicity mediation of cells evidencing surface expression of TROP-2 审中-公开证实TROP-2表面表达的细胞的细胞毒性调解公开(公告)号：US20090142263A1
公开(公告)日：2009-06-04
申请号：US12229187
申请日：2008-08-20
IPC分类号： A61K51/10 , C07K16/00 , A01N1/02 , G01N33/574 , A61K39/395
CPC分类号： C07K16/30 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , G01N33/57484
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
54.发明授权公开(公告)号：US07507537B2
公开(公告)日：2009-03-24
申请号：US11592516
申请日：2006-11-03
IPC分类号： A61K39/395 , A61K51/00
CPC分类号： G01N33/566 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K49/0058 , A61K51/1027 , A61K2039/505 , B82Y5/00 , C07K16/00 , C07K16/2884 , C07K16/30 , C07K16/3015 , C07K2317/73 , G01N33/5011 , G01N33/5014 , G01N33/5082 , G01N33/56972 , G01N33/574 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57449 , G01N33/57484 , A61K2300/00
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用癌变疾病修饰抗体（CDMAB）或其衍生物，任选与一种或多种化学治疗剂组合，作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMABs的结合测定法。
-
55.发明申请公开(公告)号：US20090068182A1
公开(公告)日：2009-03-12
申请号：US12228682
申请日：2008-08-13
IPC分类号： A61K39/395 , C07K16/30 , A61P35/00 , G01N33/574 , C12N5/12
CPC分类号： C07K16/2803 , A61K47/6803 , A61K47/6813 , A61K47/6815 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6859 , A61K51/1027 , A61K51/1045 , A61K51/1051 , A61K51/1057 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/303 , C07K2317/73 , G01N33/574
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
公开(公告)号：US07488475B2
公开(公告)日：2009-02-10
申请号：US11370203
申请日：2006-03-07
IPC分类号： A61K39/395 , C12P21/04 , C12P21/08 , C07K16/00
CPC分类号： C07K16/3015 , A61K47/6851 , A61K47/6855 , A61K47/6869 , A61K51/1051 , A61K51/1072 , A61K2039/505 , C07K16/30 , C07K16/3069
摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译： 本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。
-
公开(公告)号：US20090022660A1
公开(公告)日：2009-01-22
申请号：US12172601
申请日：2008-07-14
IPC分类号： A61K51/10 , C07K16/30 , C12N5/20 , A61P35/00 , G01N33/567 , A61K39/395
CPC分类号： C07K16/3023 , A61K47/6857 , A61K51/1054 , A61K2039/505
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
-
58.发明申请Cytotoxicity mediation of cells evidencing surface expression of TROP-2 审中-公开证实TROP-2表面表达的细胞的细胞毒性调解公开(公告)号：US20080305104A1
公开(公告)日：2008-12-11
申请号：US12082647
申请日：2008-04-11
IPC分类号： A61K39/395 , G01N33/574 , C07K16/30 , C07K16/46 , A61P35/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/734 , G01N33/57407 , G01N33/57484 , G01N33/57492
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
59.发明授权公开(公告)号：US07420041B2
公开(公告)日：2008-09-02
申请号：US11709898
申请日：2007-02-22
IPC分类号： C07K16/00
CPC分类号： C07K16/30 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , G01N33/57484
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
公开(公告)号：US20080206133A1
公开(公告)日：2008-08-28
申请号：US12017886
申请日：2008-01-22
IPC分类号： A61K51/00 , C07K16/18 , C12N5/06 , G01N33/574 , A61P43/00 , A61K38/21 , C12N9/00 , A61K39/395
CPC分类号： C07K16/30 , A61K47/6813 , A61K47/6815 , A61K47/6851 , A61K51/1045 , A61K2039/505 , G01N33/5017 , G01N33/57492
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.072 秒)
